Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

15.4%

2 terminated/withdrawn out of 13 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

15%

2 trials in Phase 3/4

Results Transparency

38%

3 of 8 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
4(40.0%)
Phase 1
4(40.0%)
Phase 3
2(20.0%)
10Total
Phase 2(4)
Phase 1(4)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT04055454Phase 1Completed

A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)

Role: collaborator

NCT04891809Phase 2Active Not Recruiting

Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM

Role: collaborator

NCT03792763Phase 2Completed

Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients

Role: collaborator

NCT02502903Phase 1Completed

Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders

Role: collaborator

NCT04195373Phase 1Withdrawn

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

Role: collaborator

NCT02113800Phase 2Completed

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Role: collaborator

NCT02331927Phase 2Unknown

PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer

Role: collaborator

NCT01627379Phase 3Terminated

Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer

Role: collaborator

NCT01326767Phase 3Completed

Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring

Role: collaborator

NCT01073462Completed

Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years

Role: collaborator

NCT01077271Completed

Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA

Role: collaborator

NCT01084668Completed

Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs

Role: collaborator

NCT01259518Phase 1Unknown

Dose Escalation Study of TriN2755 in Advanced Solid Tumors and Sarcomas

Role: collaborator

All 13 trials loaded